Mochi Health Review: What the Advertised Prices Leave Outside Your First Payment

01Start with the payment collected today, not the monthly equivalent

The clearest membership offer is also the easiest to misread: $199 for the first 12 months, with $199 due today. Mochi displays a $17-per-month equivalent and advertises “Save $39,” but the collection instruction is the operative budgeting detail. This particular offer requires the stated first-year payment upfront. It does not establish a recurring $17 monthly debit, a medication allowance or the amount due when those first 12 months end. The advertised savings are Mochi’s claim, not an independently calculated comparison.

A separate banner says customers can get $79 off membership, with the first month free specifically on the one-month plan. That promotion should not be folded into the annual offer or described as a free first month of treatment. The supplied material does not establish the full subsequent billing schedule for that plan. Our guide to understanding the first payment explains why the checkout amount and an advertised monthly figure can answer different questions.

Before selecting either offer, ask for a written summary identifying the plan, the amount charged immediately, the next charge date and the next charge amount. Also ask what happens financially if the clinical evaluation does not lead to a prescription. These are meaningful gaps in the supplied documentation, not evidence that Mochi necessarily charges a particular undisclosed fee. A membership purchase should be evaluated separately from whether a clinician ultimately recommends medication.

02The medication prices have different units and conditions

Mochi’s injectable pages advertise compounded, once-weekly subcutaneous semaglutide starting at $60 and compounded, once-weekly subcutaneous tirzepatide starting at $90. Both require membership in addition to the medication payment. Both pages say price varies with the prescribed dose and require a written prescription from a licensed provider. Crucially, the quoted price blocks do not identify the supply period. Calling either amount a monthly medication price would add a condition that the supplied evidence does not establish.

The oral semaglutide page is more specific about its price interval: it advertises a compounded once-weekly oral pill starting at $62 per month, plus membership, at the prescriber’s discretion. That is still a starting price rather than a guaranteed individual total. The route and presentation matter when requesting a quote; an oral compounded product and an injectable compounded product should not be treated as interchangeable line items merely because their ingredient names overlap.

The table separates the documented price units rather than combining them into a misleading total. Ask the prescribing team or billing staff to identify the exact product, presentation, supply quantity, billing interval and membership requirement in the same written quote. Our explanation of what program prices include offers a framework for keeping care access, medication and diagnostics separate. None of the supplied injectable price blocks supports assuming a calendar month or a four-week supply.

03Membership includes access, but not every care expense

The medication-page process description says unlimited visits with the care team are included in membership. The homepage adds video visits as needed, ongoing nutrition and wellness guidance, and follow-up laboratory monitoring. Mochi also invites patients to choose a medical provider it describes as board certified and a registered dietitian. These are substantive service descriptions, although this review did not independently verify individual credentials or establish how quickly any particular professional can be booked.

The important exclusion is explicit: medications and diagnostic services are not included in the membership subscription. A reference to ordering labs or using follow-up labs therefore does not establish that the laboratory bill is covered. Separately, the insurance-care block says visits are billed through insurance and the copay is shown before committing. “Unlimited visits” should not be read as proof that every insured visit has no additional patient cost. Ask which billing arrangement governs your enrollment and which services create separate bills.

04Insurance assistance is a service, not a coverage guarantee

Mochi says that, if medication is prescribed, it handles prior authorization and arranges delivery or local pickup. It also advertises cash-pay and compounded options for people without insurance. Those statements describe assistance and possible access routes; they do not establish that an insurer will approve a particular prescription or that the medication price will match a website starting figure. The supplied pages also do not resolve every self-pay or insured-plan configuration represented by the website’s selectors.

The distinction between visit coverage and drug coverage is especially important here. NIDDK notes that some insurance plans cover weight-management medicines and others do not; individual coverage needs confirmation with the plan. Mochi’s statement that a visit copay is displayed before commitment is useful, but it does not settle the pharmacy benefit. Use the questions in our insurance and self-pay guide to request separate answers about the consultation, medication, prior authorization and any diagnostic bill.

05Follow the service chain before assigning responsibility

Mochi describes an intake questionnaire covering health history, followed on its tirzepatide page by a live, 30-minute video visit with a doctor. That duration describes the appointment itself, not a promise of an appointment within 30 minutes. The homepage says labs may be ordered when needed. Medication remains conditional on clinical prescribing discretion. The supplied pages do not establish a minimum age, complete eligibility criteria, appointment availability or a clinical-review deadline, so enrollment should not be treated as a guaranteed prescription.

The corporate notice also matters when identifying who owes which service. It says professional medical services are delivered by licensed physicians and clinicians affiliated with independently owned and operated professional practices. Mochi Health Corp. says it provides administrative and technology services, not professional medical services itself. Its advertised 24/7 care-team support includes insurance and prior-authorization assistance, but no response-time guarantee is given. Before paying, identify the treating practice and the contact route for clinical concerns, billing disputes and pharmacy problems; these need not be the same responsibility.

06A broad catalog does not establish a price or equivalent evidence

The homepage lists more than the three compounded products with quoted starting prices. Its catalog includes injectable Zepbound, Wegovy, Mounjaro and Ozempic, plus oral products labeled Foundayo and Wegovy Pill. It also presents compounded oral orforglipron and oral metformin. These listings show the breadth of Mochi’s advertised options, not a personalized treatment menu or proof that each is available in every state. The supplied material does not give a complete price schedule for these other options.

Mochi’s product descriptions distinguish weight-management offerings from diabetes offerings: its Mounjaro entry describes blood-sugar control in adults with type 2 diabetes, while its Ozempic entry also mentions cardiovascular and kidney benefits in eligible adults. Statements about product approvals—including the homepage’s Wegovy Pill description—are attributed to Mochi here, not independently verified through this review. FDA approval concerns a specific product; it does not approve Mochi as a service or extend to a compounded preparation sharing an ingredient name.

For compounded products, Mochi discloses that they are not FDA approved or evaluated for safety, effectiveness or quality. FDA’s guidance recommends compounded drugs when an individual’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. Nonapproval alone does not prove clinical inequivalence. Equally, published trials of specific studied products do not establish results for Mochi’s compounded preparations, oral routes or individual patients. A lower advertised price cannot resolve those evidence questions.

07Pharmacy and delivery details belong in the budget

Mochi advertises purchasing medication through its network of pharmacies with “reliable shipping,” and its medication pages describe prescription fulfillment and delivery to the patient’s door. The homepage also mentions local pickup when arranging medication access. The supplied excerpts do not identify the pharmacy that would dispense a particular prescription or the pharmacy that would compound it. Dispensing and compounding are different responsibilities; a network reference alone does not identify who performs either task for an individual order.

There is no documented dispatch deadline, arrival window, cold-chain procedure or replacement policy in these materials. That leaves practical questions about separate shipping charges, missed deliveries and responsibility for an unusable shipment. FDA explicitly advises not using an injectable GLP-1 drug that arrives warm or with insufficient refrigeration and contacting the provider or dispensing pharmacy. Ask for those contact details and the replacement process before shipment, rather than assuming the general shipping claim answers a temperature or reimbursement problem.

08Cancellation language does not settle the unused balance

Mochi advertises personalized treatment options, “No hidden fees” and “Cancel anytime.” Those are provider claims, not a substitute for the applicable billing terms. With a $199 first-year payment, the unresolved question is what cancellation does to money already collected. The supplied pages do not explain a prorated refund, a nonrefundable balance, the cancellation procedure or the effect on an outstanding prescription. A refund-policy link exists, but the policy itself was not among the supplied documents.

Renewal terms are another material gap: the first-year offer does not establish the subsequent membership price, charge date or notice requirement. Before enrollment, retain the applicable checkout terms and request written answers about stopping renewal, prepaid balances and medication orders already being processed. Our guide to cancellation and refunds explains why these are separate questions. Mochi also discloses compensation for featured member testimonials; those accounts should not replace documented terms or independent evidence when deciding whether the financial commitment fits.

Questions & answers

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

1. FDA concerns with unapproved GLP-1 drugs used for weight loss ↗
2. NIDDK: prescription medications for overweight and obesity ↗
3. Wilding et al. (2021): STEP 1 semaglutide trial ↗
4. Jastreboff et al. (2022): SURMOUNT-1 tirzepatide trial ↗
5. Mochi Health — medications/compounded semaglutide ↗
6. Mochi Health — medications/compounded tirzepatide ↗
7. Mochi Health — official website ↗
8. Mochi Health — medications/compounded semaglutide pill ↗

Continue reading

• Why Your First GLP-1 Payment Can Differ From the Advertised Monthly Price
• What a GLP-1 Program Price Actually Includes
• Insurance and Self-Pay: Questions Before Choosing a GLP-1 Program
• Canceling a GLP-1 Subscription: What Happens to the Money?